The trials of anakinra
- 1 September 2004
- journal article
- Published by Elsevier in The Lancet
- Vol. 364 (9437) , 827-828
- https://doi.org/10.1016/s0140-6736(04)16999-7
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysisHealth Technology Assessment, 2004
- Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexateArthritis & Rheumatism, 2004
- Targeting IL-1 in inflammatory disease: new opportunities for therapeutic interventionNature Reviews Drug Discovery, 2004
- Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockadeArthritis & Rheumatism, 2004
- Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo‐controlled trialArthritis & Rheumatism, 2003
- The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluationHealth Technology Assessment, 2002
- Assessing Whether to Perform a Confirmatory Randomized Clinical TrialJNCI Journal of the National Cancer Institute, 1996